Drug Development Pipeline
SPX-101 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
Phase one and two studies to test the safety and effectiveness of SPX-101 were conducted outside of the US. No further development in CF is planned at this time.
This program was sponsored by Spyryx Biosciences and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More